Weight loss jabs linked to potentially fatal side effects
Some cases of pancreatitis reported to be linked to GLP-1 medicines (glucagon-like peptide-1 receptor agonists) have been fatal.
Data from the medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), shows that since the drugs were licensed there have been hundreds of cases of acute and chronic pancreatitis among people taking GLP-1 medicines.
The new weight management medication 'Tirzepatide' (brand name Mounjaro®) is shortly being made available to NHS patients to support weight loss. Access is prioritised for those with the greatest clinical need.
You can find out more at: https://t.co/Ahd6YqXIif pic.twitter.com/WLwEfZM2qR
This includes:
These cases are not confirmed as being caused by the medicines, but the person who reported them suspected they may be.
Review your ICB's local policy about treating patients with tirzepatide (Mounjaro) for weight management in a primary care setting and visit: https://t.co/03msJjjTU9 pic.twitter.com/YcfHOz32fx
Nonetheless, Yellow Card Biobank project, launched by the MHRA and Genomics England, will see researchers examine whether cases of pancreatitis linked to GLP-1 drugs may be influenced by peoples genetic makeup.
The MHRA is calling for people who are taking GLP-1 medicine who have been admitted to hospital due to acute pancreatitis to submit a report to its Yellow Card scheme.
When a Yellow Card report is received, the MHRA will contact patients to ask if they would be willing to take part in the study.
Patients will be asked to submit more information and a saliva sample which will be assessed to explore whether some people are at a higher risk of acute pancreatitis when taking these medicines due to their genes.
GLP-1 agonists can lower blood sugar levels in people living with type 2 diabetes and can also be prescribed to support some people with weight loss.
🧵Weight loss jab roll out 'positive for patients' but with implications for general practice that must be considered.
Our Chair Kamila Hawthorne has featured widely in the national press and broadcast media responding to the phased roll-out of Mounjaro prescriptions by NHS… pic.twitter.com/fb2KdaXIou
Chronic stress and poor sleep are major weight loss blockers. Stress increases cortisol, a hormone linked to fat retention, especially around the abdomen. Sleep deprivation increases ghrelin (hunger hormone) and decreases leptin (fullness hormone), making you more likely to overeat and less likely to move.
You're also more impulsive and less motivated when sleep-deprived, making it harder to stick to your diet and exercise routine. As a solution, prioritise stress management techniques (like mindfulness or journaling), and aim for 7-9 hours of sleep per night.
Medical issues such as PCOS, diabetes, hypothyroidism, or insulin resistance can all interfere with weight loss. Similarly, certain medications (like antidepressants or steroids) may cause weight gain or inhibit fat loss.
If weight loss stalls despite doing everything right, consult your GP to rule out or address any underlying conditions. If you have a known medical condition, it's important to stay up to date with your routine reviews and inform your GP or specialist about any weight loss treatments you're using. Regular follow-up helps ensure your treatment plan remains safe and effective.
More Mounjaro news...
Recent estimates suggest that about 1.5 million people in the UK are taking weight loss jabs.
Health officials have suggested that they can help to turn the tide on obesity, but have stressed they are not a silver bullet and do come with side effects.
Most side effects linked to the jabs are gastrointestinal including nausea, constipation and diarrhoea.
And the medical regulator recently warned that Mounjaro may make the oral contraceptive pill less effective in some patients.
Dr Alison Cave, MHRA's chief safety officer, said: 'Evidence shows that almost a third of side effects to medicines could be prevented with the introduction of genetic testing, it is predicted that adverse drug reactions could cost the NHS more than £2.2 billion a year in hospital stays alone.
'Information from the Yellow Card Biobank will help us to better predict those most at risk of adverse reactions – enabling patients across the UK to receive the safest medicine for them, based on their genetic makeup.
'To help us help you, we're asking anyone who has been hospitalised with acute pancreatitis while taking a GLP-1 medicine to report this to us via our Yellow Card scheme.
'Even if you don't meet the criteria for this phase of the Biobank study, information about your reaction to a medication is always extremely valuable in helping to improve patient safety.'
Professor Matt Brown, chief scientific officer of Genomics England, said: 'GLP-1 medicines like Ozempic and Wegovy have been making headlines, but like all medicines there can be a risk of serious side effects.
'We believe there is real potential to minimise these with many adverse reactions having a genetic cause.
'This next step in our partnership with the MHRA will generate data and evidence for safer and more effective treatment through more personalised approaches to prescription, supporting a shift towards an increasingly prevention-focused healthcare system.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
North Wales Chronicle
3 minutes ago
- North Wales Chronicle
Elderly forced out of Gwynedd communities amid care stand-off
Kevin Edwards, managing director at the Meddyg Care Group, claimed a health board is refusing to cover the 'true cost' of services provided at his care homes in Porthmadog and Criccieth, meaning people are going to homes further afield. However, Betsi Cadwaladr University Health Board (BCUHB) has insisted that it is 'committed' to providing care for people across North Wales 'as close to home as is clinically safe'. It also argued that it provides many care packages 'well beyond' its core funding rates based on clinical need. Mr Edwards claimed: 'Because we won't accept their base cost, they are not recommending our homes to Gwynedd families.' He claimed this meant some were ending up in homes far from their communities, and the support of their friends and relatives. The health board has responded by saying it is not legally allowed to recommend which homes people choose. He pointed to the difference between what care homes in rural Gwynedd needed, and the fee the health board was willing to pay, was between £40 and £80 per week per resident. 'NHS care should be free to people who need it in their local area, but people are being forced out of the area because homes in rural Gwynedd will not accept the basic fee BCUHB is prepared to pay,' he said. He added that his home provided care through the medium of Welsh but added if people go further afield that may not be the case. 'BCUHB do the costings on their fee, in my view, on the back of a fag packet,' he said and urged the board to adopt a toolkit used to set care funding fees, called CareCubed. 'How can our costs in a rural setting be the same as a home in an urban setting, somewhere in the middle of Rhyl, Llandudno, or Wrexham for instance?' He added. Mario Kreft MBE, chair of social care champions Care Forum Wales, said: 'One of the most important things for families is the location of the home where their loved ones will be living. 'The vast majority of people choose a care home in a community where they want to be in, it's so important. 'This issue highlights what we are facing in North Wales, and that's a health board which has been promising methodology for more than a decade. 'They should be meeting government guidance on this, it's outrageous that they are not.' He added it caused 'further anxiety' to future residents and families, delaying hospital discharges, and saw people taken to parts of the country they don't want to be in, and highlighted a north-south divide over fees. Betsi Cadwaladr University Health Board's Chief Operating Officer Tehmeena Ajmal said: 'We are committed to providing care for people across North Wales as close to home as is clinically safe. 'We understand that these are challenging times for everyone, and we must ensure that our resources are used fairly and appropriately for all. 'For people who are eligible for NHS Continuing Healthcare (CHC), each person receives an individual assessment. Many people are supported with care packages that go well beyond our published core funding rate, based on their clinical needs. 'It's important to note that we are not legally allowed to recommend which care home families should choose. We must remain fair and cannot show preference for one independent provider over another. 'We continue to admit patients into all nursing care homes in Gwynedd. Currently, there are only very small numbers of people in hospitals waiting for placements in EMI (Elderly Mentally Infirm) nursing care homes. 'We are fully committed to making sure people can receive care in the Welsh language, and—where possible—stay close to their communities, families, and friends. 'These are all important factors when we agree on care placements and funding. 'As a region, we have reviewed a number of fee-setting tools, including CareCubed, which several local authorities have started using. 'We are working closely with them to review and assess this approach.'
Sky News
10 minutes ago
- Sky News
Plans unveiled for NHS funding to be linked to patient feedback
NHS funding could be linked to patient feedback under new plans, with poorly performing services that "don't listen" penalised with less money. As part of the "10 Year Health Plan" to be unveiled next week, a new scheme will be trialled that will see patients asked to rate the service they received - and if they feel it should get a funding boost or not. It will be introduced first for services that have a track record of very poor performance and where there is evidence of patients "not being listened to", the government said. This will create a "powerful incentive for services to listen to feedback and improve patients' experience", it added. Sky News understands that it will not mean bonuses or pay increases for the best performing staff. NHS payment mechanisms will also be reformed to reward services that keep patients out of hospital as part of a new 'Year of Care Payments' initiative and the government's wider plan for change. 2:04 Speaking to The Times, chief executive of the NHS Confederation Matthew Taylor expressed concerns about the trial. He told the newspaper: "Patient experience is determined by far more than their individual interaction with the clinician and so, unless this is very carefully designed and evaluated, there is a risk that providers could be penalised for more systemic issues, such as constraints around staffing or estates, that are beyond their immediate control to fix." He said that NHS leaders would be keen to "understand more about the proposal", because elements were "concerning". Health Secretary Wes Streeting said: "We will reward great patient care, so patient experience and clinical excellence are met with extra cash. These reforms are key to keeping people healthy and out of hospital, and to making the NHS sustainable for the long-term as part of the Plan for Change." In the raft of announcements in the 10 Year Health Plan, the government has said 201 bodies responsible for overseeing and running parts of the NHS in England will be scrapped. These include Healthwatch England, set up in 2012 to speak out on behalf of NHS and social care patients, the National Guardian's Office, created in 2015 to support NHS whistleblowers, and the Health Services Safety Investigations Body (HSSIB). Elsewhere, the new head of NHS England Sir Jim Mackey said key parts of the NHS appear "built to keep the public away because it's an inconvenience". "We've made it really hard, and we've probably all been on the end of it," he told the Daily Telegraph.
The Independent
17 minutes ago
- The Independent
‘Cervical cancer has affected generations of my family - NHS changes mean women like me could be missed out'
A woman whose grandmother and mother both had cervical cancer has called for the reversal of recent changes lengthening the intervals between life-saving screenings. Gemma Barley, 34, had to undergo a biopsy in January 2022 after her regular three-year check-up found abnormal cells in her cervix - despite her previous screening being completely clear. She fears that if she had been subject to new NHS England rules - which have lengthened the time between check-ups to five years - the outcome could have been worse. 'After a regular smear check-up in 2022 I got a letter to say we've found something abnormal in your smear and told I needed a biopsy,' the mother-of-one said. 'It was like my full life had flashed before my eyes. I thought my son was going to be left without a mum. It was horrifying.' Cervical cancer has affected Ms Barley's family for generations. She lost her grandmother to the disease aged 54, just three months after being diagnosed in 2004. Her mother was also diagnosed with cervical cancer in 2018 and had to undergo a hysterectomy to mitigate the risks of the disease. Ms Barley waited four weeks for her results - which said the cells were not cancerous. But the psychology graduate said the experience proves how quickly things can change, and fears recent changes to screenings for cervical cancer could 'put women's lives at risk'. Women aged 25 to 49 who test negative for human papillomavirus (HPV) will now be invited to cervical screening every five years instead of every three, under new NHS guidelines. According to Cancer UK, nearly all cases of cervical cancer are caused by HPV. Most of the time HPV is cleared from the body by itself, but some types can cause cancer if they stay in the body for a long time so require extra monitoring. After seeing the planned changes, Ms Barley started a petition to have them reversed and said: 'I was really angry when I saw the changes. Because of my first-hand experience, it petrified me. 'My first smear was fine, and I'd seen no significant changes in my life since then. But then my second smear found abnormalities. That's how quickly that could change - and yet they're happy to extend it by a further two years.' The change, set to take effect next month in England, follows recommendations from the UK National Screening Committee. According to analysis from King's College London, extending the screening interval to five years for HPV-negative women is just as safe as the current three-year interval, with a similar rate of cancer detection. An NHS England spokesperson said: 'We recognise that changes to cervical screening can seem worrying but want to reassure everyone that this new approach is based on robust scientific evidence and an expert recommendation from the UK National Screening Committee. 'The NHS cervical screening programme tests for HPV and uses a better and more accurate test than before. This means if you test negative for HPV, you don't need to be screened as often as your risk of developing cervical cancer is very low. If you test positive for HPV, we'll monitor you more closely with additional tests and follow-up appointments. 'This personalised approach ensures everyone receives the right level of screening based on their individual risk factors, providing better protection while reducing unnecessary procedures.' A Department of Health and Social Care spokesperson said: 'These changes are based on robust scientific evidence and an expert recommendation from the UK National Screening Committee. 'The NHS cervical screening programme tests for HPV which is a more accurate test than the old cytology (smear) test, therefore intervals for those not at high risk can be safely extended from three to five years. 'If you test positive for HPV, you can be assured you will be monitored closely with additional tests and follow-up appointments.'
